TomoTherapy’s New TomoHD(TM) System Expands Ability to Treat Patient Population With Single Radiation Therapy Device

MADISON, WI--(Marketwire - October 21, 2009) -

TomoTherapy Incorporated (NASDAQ: TOMO) today announced that it has extended its suite of advanced radiation therapy solutions with the addition of the TomoHD™ treatment system, an efficient, all-purpose new system designed to make it easier for any radiation oncology department to adopt TomoTherapy® technology for its patient population. The TomoHD treatment system will be introduced during the upcoming Annual Meeting of the American Society for Radiation Oncology (ASTRO), November 1-5, 2009, in Chicago.

Fully-featured to meet more needs
The new TomoHD treatment system bundles technologies previously available only as options for the TomoTherapy Hi·Art® system, as well as new core technologies. The result is a single comprehensive solution that efficiently handles both common and complex clinical indications with ease, broadening the possibilities for any radiation oncology practice and the patients it serves.

The TomoHD treatment system combines TomoHelical(SM) and TOMODIRECT(SM) delivery modes. The TomoHelical technique affords continuous 360-degree delivery for gold-standard treatment quality and targeting of complex volumes. The TomoDirect modality -- introduced in 2008 -- offers a discrete-angle delivery option, with 3D conformal radiation therapy (3DCRT) capabilities, for highly efficient treatment of more routine indications. In both delivery modes, clinicians follow the same basic process for planning, imaging and treating targets of up to 160 cm in length with no need to reposition the patient and no need for field junctioning. In addition to extended delivery versatility, the TomoHD treatment system comes complete with 1, 2.5 and 5 cm primary collimator settings that enable users to select the right beam slice width for each case, depending upon conformity and efficiency needs.

Finely tuned for efficiency and performance
The TomoHD treatment system incorporates functional enhancements to significantly improve enterprise-wide integration (including Oncology Information System connectivity), usability and performance.

The streamlined new design of the TomoHD system gives it the ability to accommodate even smaller bunkers than are currently recommended for the Hi·Art treatment system and its CT scanner-like footprint. The TomoHD treatment system also includes large touch-screen Positioning Control Panels (PCPs), which allow for high-fidelity positioning adjustments of 0.1 mm in X, Y and Z directions, and a hands-free patient unload feature. The TomoHD system also integrates many infrastructure advances to maximize uptime and operational efficiency.

To aid workflow, the TomoHD system includes 14 blade computing power, which facilitates simultaneous optimization of multiple treatment plans -- at twice the speed of the Hi·Art treatment system’s standard configuration.

The TomoHD treatment system further increases departmental efficiency with the integration of the Tomo Quality Assurance (TQA™) application, a calendar-based productivity tool that simplifies the collection and analysis of system performance information, offering trending and reporting of many parameters that allow physicists to monitor machine performance.

Building upon experience, for the future
The TomoTherapy radiation therapy platform has been used to extend clinical reach and improve treatment quality at cancer centers around the world. The TomoTherapy platform, which leverages a CT scanner-like ring gantry design, was clinically introduced in July 2003 with the installation of the first TomoTherapy Hi·Art treatment system. Since then, more than three million treatment fractions have been delivered on the platform -- targeting tumors throughout the body with the aid of daily, pre-treatment CT imaging for heightened accuracy and a helical delivery pattern of intensity-modulated radiation therapy (IMRT) for increased precision. During this time, hundreds of scientific papers have also been published documenting the diverse advantages that the TomoTherapy platform offers.

The TomoHD treatment system benefits from the evolution of the TomoTherapy platform and will accommodate future innovations -- including the Advanced TomoTherapy Delivery Technique*, a research initiative expected to reduce treatment times by 40 percent to 70 percent, while improving treatment quality.

“The TomoTherapy platform is the most integrated, advanced radiotherapy solution available today,” said TomoTherapy CEO Fred Robertson, M.D. “The addition of the TomoHD treatment system to the product family further extends the reach of this technology, increasing the number of patients that can be served, and making it easier than ever for cancer centers to embrace the future of radiation oncology.”

On display at ASTRO, booth 1946
The new TomoHD treatment system will be on display in booth 1946 at the ASTRO Annual Meeting. TomoTherapy staff will present expanded platform capabilities and infrastructure enhancements. For more information on TomoTherapy at ASTRO, including the introduction of the TomoMobile™ relocatable radiotherapy solution in booth 1881, please visit TomoTherapy.com.

*Advanced TomoTherapy Delivery Technique is a works-in-progress and not available for sale.

About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms “expected to,” “anticipates,” “believe(s),” “will,” “can,” “expect,” or “should” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to gain customer acceptance, ability to complete development in a timely manner, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2009 TomoTherapy Incorporated. All rights reserved. The following marks as used herein in italicized or stylized text are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries: TomoTherapy, Tomo, TomoDirect, TomoHelical, TomoHD, TomoMobile, TQA, Hi·Art, and the TomoTherapy logo.